SS-31
Elamipretide (D-Arg-Dmt-Lys-Phe-NH2)
SS-31 (Elamipretide) is a mitochondria-targeting tetrapeptide that binds to cardiolipin in the inner mitochondrial membrane to optimize mitochondrial structure and function. Originally developed for mitochondrial diseases and heart failure, SS-31 enhances cellular energy production and reduces oxidative stress across multiple organ systems. It has shown promise in clinical trials for heart failure with preserved ejection fraction, Barth syndrome, and mitochondrial myopathies.
How SS-31 Works
From Injection to Results
The Science Behind It
In Plain Terms
Think of SS-31 as a special repair crew for your cellular power plants (mitochondria). It finds and fixes a key component called cardiolipin that's like the electrical wiring in these power plants. When cardiolipin works better, your cells can make more energy (ATP) and produce less harmful waste products, which means better function in your heart, muscles, and other organs.
Technical Details
SS-31 is a mitochondria-targeting tetrapeptide that selectively binds to cardiolipin, a unique phospholipid component of the inner mitochondrial membrane. This binding optimizes the structure and function of cardiolipin, which is essential for proper electron transport chain activity and mitochondrial cristae structure. By stabilizing cardiolipin, SS-31 reduces reactive oxygen species (ROS) production, enhances ATP synthesis, and improves overall mitochondrial bioenergetics across multiple cell types.
Medical Disclaimer
SS-31 (Elamipretide) is currently in Phase III clinical trials and is not yet FDA approved for general clinical use. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all investigational uses.